Advertisement

Topics

Immunicum starts enrolment in US for Phase II oncology trial

19:00 EDT 10 Aug 2017 | Net Resources International

Swedish biopharmaceutical firm Immunicum has started patient enrolment in the US for the ongoing Phase II MERECA clinical trial of its drug candidate ilixadencel to treat renal cell carcinoma.

Original Article: Immunicum starts enrolment in US for Phase II oncology trial

NEXT ARTICLE

More From BioPortfolio on "Immunicum starts enrolment in US for Phase II oncology trial"

Quick Search
Advertisement
 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...